MAY-JUN 2014

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link:

Contents of this Issue


Page 16 of 86

BEST PR ACTICES 12 MAY/JUNE 2014 | Med Esthetics Anterios (, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, has an- nounced development of a next-generation injectable botulinum toxin product, AI-09, which utilizes neither lyophilization (freeze drying) nor albumin. Unlike current neurotoxins, it will not require reconstitution and will be packaged as a ready-to-use injectable liquid. Anterios also has a topical botulinum toxin product in Phase IIb development, ANT-1207. "We're pleased to leverage our proprietary delivery technology platform to develop a new product that is complementary to ANT-1207," said Jon Edelson, MD, CEO and founder of Anterios. "Alongside ANT- 1207, AI-09 will enable us to offer the complete breadth of next-generation botulinum-based treatment modalities that physicians are seeking for the benefi t of their patients. We believe the platform has the potential to enable the development of many other proprietary biologic and small molecule products." Anyone can sue you at any time for any reason. This terrible truth can become the physician's Damocles sword. But all is not out of your hands. At the 2014 Annual Meeting of the American Society of Laser Medicine & Surgery, Matthew Avram, MD, shared the following steps that physicians can take to reduce the risk of lawsuit, while also improving patient care and physician reputation. • Patient Selection: Determine if the procedure is ap- propriate for the patient; trust your and your staff's intuition—physicians can refuse treatment; manage patient expectations • Communication: Don't rush the consult; speak clearly and in layman's terms; answer all questions; explain the procedure's risks and benefi ts • Informed Consent: Obtain informed consent; avoid technical medical terms (i.e., use 'bruising' instead of 'pur- pura' and 'redness' instead of 'erythema.') • Know Your Limits: Do only the procedures you are trained to deliver and comfortable performing • Handle Complications: Do not abandon patients with com- plications. See them the same day • Pigmented Lesions: Do not treat pigmented lesions unless you have a diagnosis, regardless of who referred the patient; perform a biopsy when in doubt. To help practices understand and abide by current HIPA A regulations, the American Medical Association has released its third edition of HIPAA: Plain & Simple: After the Final Rule. The comprehensive publication, available as an e-book with accompanying PDF forms, explains current HIPA A and HITECH regulations and offers an easy-to-understand guide to the stronger HIPA A privacy and security safeguards and new, stronger protec- tions for electronic health data. Also cov- ered: enforcement, the accounting of disclo- sures, business associ- ate contracts; and new content on migrating to operating rules and meaningful use. Avail- able at the AMA Store, Anterios Developing Next-Generation Injectable Neurotoxin AMA Updates HIPAA Guide Reduce the Risk of Litigation © THINKSTOCK B e s t P r a c t i c e s M E D 5 - 6 1 5 . i n d d 1 2 Best Practices MED5-615.indd 12 4 / 1 6 / 1 4 4 : 3 5 P M 4/16/14 4:35 PM

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - MAY-JUN 2014